Jazz Pharmaceuticals (JAZZ) total debt
Jazz Pharmaceuticals (JAZZ) carried total debt of $5.42B at the end of fiscal 2025 (December 31, 2025). That is 12.0% lower than the $6.16B of fiscal 2024. Figures as of 18 Nov 2026, 06:35 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- $5.42B
- Change on fiscal 2024
- −12.0%
- Growth, 5 years
- +21.0% a year
- Growth, 10 years
- +16.4% a year
- Highest on record
- $6.16Bfiscal 2024
- Lowest on record
- $0.00fiscal 2011
- Fiscal years on record
- 152011–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Jazz Pharmaceuticals total debt, in more detail
Over the five fiscal years to 2025 total debt grew at a compound 21.0% a year; over ten years the rate was 16.4% a year. Across the 15 fiscal years on record (2011–2025), the highest was $6.16B in fiscal 2024 and the lowest $0.00 in fiscal 2011.
Total debt was 1.3× shareholders' equity at the end of fiscal 2025.
Total debt by fiscal year
Jazz Pharmaceuticals total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | $5.42B | 12.0% down | 1.3× | |
| 2024 | $6.16B | 6.4% up | 1.5× | |
| 2023 | $5.79B | 0.4% down | 1.5× | |
| 2022 | $5.81B | 3.9% down | 1.9× | |
| 2021 | $6.05B | 188.8% up | 1.5× | |
| 2020 | $2.09B | 30.3% up | 0.6× | |
| 2019 | $1.61B | 0.7% up | 0.5× | |
| 2018 | $1.60B | 1.0% up | 0.6× | |
| 2017 | $1.58B | 22.1% down | 0.6× | |
| 2016 | $2.03B | 70.8% up | 1.1× | |
| 2015 | $1.19B | 11.5% down | 0.7× | |
| 2014 | $1.34B | 144.1% up | 1.0× | |
| 2013 | $549.98M | 20.4% up | 0.4× | |
| 2012 | $456.76M | — | 0.4× | |
| 2011 | $0.00 | — | 0.0× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Total debt at health care companies of similar size
| Company | Total debt | Fiscal year |
|---|---|---|
| Neurocrine Biosciences NBIX | $415.30M | 2025 |
| Ascendis Pharma ASND | €871.79M | 2025 |
| ICON ICLR | $3.56B | 2025 |
| Jazz Pharmaceuticals JAZZ | $5.42B | 2025 |
| Solventum SOLV | $5.04B | 2025 |
| BridgeBio Pharma BBIO | $1.86B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Jazz Pharmaceuticals, figure by figure
- Jazz Pharmaceuticals market cap
- Jazz Pharmaceuticals revenue
- Jazz Pharmaceuticals earnings
- Jazz Pharmaceuticals earnings per share (EPS)
- Jazz Pharmaceuticals P/E ratio
- Jazz Pharmaceuticals P/S ratio
- Jazz Pharmaceuticals P/B ratio
- Jazz Pharmaceuticals free cash flow
- Jazz Pharmaceuticals operating margin
- Jazz Pharmaceuticals dividend
- Jazz Pharmaceuticals shares outstanding
- Jazz Pharmaceuticals cash on hand
- Jazz Pharmaceuticals total assets
- Jazz Pharmaceuticals return on equity (ROE)
- Jazz Pharmaceuticals return on invested capital (ROIC)
Jazz Pharmaceuticals (JAZZ) overview: price, valuation and scorecardAll health care companies by market value
Jazz Pharmaceuticals total debt: questions and answers
How much debt does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals (JAZZ) carried total debt of $5.42B at the end of fiscal 2025 (December 31, 2025). That is 12.0% lower than the $6.16B of fiscal 2024.
What is the growth rate of Jazz Pharmaceuticals's total debt?
Over the five fiscal years to 2025 total debt grew at a compound 21.0% a year; over ten years the rate was 16.4% a year.
What are the highest and lowest total debt figures on record for Jazz Pharmaceuticals?
Across the 15 fiscal years on record (2011–2025), the highest was $6.16B in fiscal 2024 and the lowest $0.00 in fiscal 2011.
How does Jazz Pharmaceuticals's debt compare with its equity?
Total debt was 1.3× shareholders' equity at the end of fiscal 2025.
How is Jazz Pharmaceuticals's total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Jazz Pharmaceuticals (JAZZ) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/JAZZ/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.